Work

Acute Kidney Injury Biomarkers - Needs, Present Status, and Future Promise.

Year: 2006

Type: article

Abstract: In the last decade, great progress has been made in dissecting the molecular mechanisms of Acute Kidney Injury (AKI; Also known as Acute Renal Failure, ARF)); however, translation of these findings to therapeutics of clinical utility has lagged. Development of therapeutics for AKI is has been slow and garnered limited industry interest because AKI is poorly characterized and difficult to diagnose early. Additional challenges include an inability to predict severity, measure progression, or response to therapy, all of which add complexity and risk to clinical trials. A standard definition of AKI is being developed, which will facilitate progress greatly. However, the over-reliance on serum creatinine as a marker of renal function and injury and the absence of additional disease markers has hampered clinical trials for AKI. Serum creatinine in AKI has poor sensitivity and specificity; patients are not in steady state, hence serum creatinine lags behind both renal injury and renal recovery. Conventional urine markers (casts, fractional excretion of sodium) are non-specific and insensitive. Reliance on traditional markers slows recognition of AKI and hence delays nephrologic consultation and discontinuation of nephrotoxic agents, and complicates drug development.

Source: PubMed

Authors: Hua Zhou, Stephen M Hewitt, Peter S T Yuen, Robert A Star

Institutions: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases

Language: English

Topic: Acute Kidney Injury Research

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institutes of Health

Award: Early Detection Of Renal Injury